Olga Yu. Sorokina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Olga Yu. Sorokina has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Beatrisa Albertovna Volel
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
12 shared publications - Dmitry Sergeevich Petelin
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
11 shared publications - Sergey A. Semin
Sechenov First Moscow State Medical University (Sechenov University)
7 shared publications - Yu. V. Dolgopolova
Sechenov First Moscow State Medical University (Sechenov University)
4 shared publications - Daria V. Troshina
Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Roman Vitalievich Akhapkin
Serbsky National Medical Research Center of Psychiatry and Narcology
3 shared publications
Latest Publications
- Open Access
- 17 October 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (4) , 40-48
Neurosteroid and Neuroinflammatory Markers of Therapeutic Dynamics in Unipolar Depression in Women of Reproductive Age
Background : Chronic stress can disrupt the adaptive mechanism consisting of negative regulation of the hypothalamicpituitary-adrenal (HPA) axis by endogenous neurosteroids, thereby contributing to the development of stress-related affective disorders. However, the dynamics of neurosteroid status during treatment has not been sufficiently studied. The aim was to evaluate the relationship between the therapeutic dynamics of patients with unipolar depression and changes in their neurohormonal status. Patients and Methods : the study included 42 females of reproductive age with unipolar depression (39; 93% completed the study). Average age of patients was 33.5 ± 2.1 years. A diagnosis of depressive episode within recurrent depressive disorder was established in 17 patients (43.6%), a single depressive episode in 10 (25.6%), and dysthymia in 12 (32.4%). The patients' condition was assessed before the start of therapy in the hospital and three months later using a battery of psychometric tests (MADRS, HAM-A, Holmes-Ray Stress Rating Scale) and laboratory tests (progesterone, cortisol, total cholesterol, and C-reactive protein in blood). Results : the average total MADRS score decreased from 22.82 ± 1.2 at the beginning to 9.13 ± 1.4 ( p < 0.001) at the end point. The severity of anxiety according to the HAM-A scale decreased from 17.91 ± 0.792 to a level comparable to the population level — 6.13 ± 0.766 ( p < 0.001). 30 patients (76.9%) achieved a response. Complete remission was registered in 19 (48.7%) after treatment. Concerning the laboratory data, the cortisol level changed signi cantly -— from 409 nmol/l to 273 nmol/l ( p = 0.005), the cortisol to progesterone ratio decreased from 48.5 to 16.06 ( p = 0.006). Changes in progesterone indicators from 8.50 nmol/l to 17.51 nmol/l ( p = 0.118), total cholesterol ( p = 0.801), CRP ( p = 0.945) did not reach statistical signi cance. Cortisol levels were significantly lower in responders (242.5 ± 38.9) than in non-responders (315.2 ± 43.2), (Exp(B) = 0.413, p = 0.008). Progesterone levels were higher in responders (19.8 ± 2.3) than in non-responders (15.6 ± 3.3), (Exp(B) = 1.314, p = 0.044). Differences in total cholesterol levels between the responder and nonresponder groups (Exp(B) = 0.618, p = 0.036) are significant predictors of therapeutic response. Differences in CRP levels between responders and non-responders were not statistically signifi cant. High Holmes-Rey Depression Inventory scores (260.86 ± 12) did not associate with other psychometric and laboratory parameters. Conclusions : peripheral markers of neuroin ammation, endogenous neurosteroid system activity, and the HPA axis demonstrate signi cant changes during treatment of unipolar depression in women of reproductive age. Evaluating the ef cacy of neurosteroid analogs in antidepressive therapy is a promising direction.
- 17 October 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (4) , 40-48
Open AccessNeurosteroid and Neuroinflammatory Markers of Therapeutic Dynamics in Unipolar Depression in Women of Reproductive Age
Background : Chronic stress can disrupt the adaptive mechanism consisting of negative regulation of the hypothalamicpituitary-adrenal (HPA) axis by endogenous neurosteroids, thereby contributing to the development of stress-related affective disorders. However, the dynamics of neurosteroid status during treatment has not been sufficiently studied. The aim was to evaluate the relationship between the therapeutic dynamics of patients with unipolar depression and changes in their neurohormonal status. Patients and Methods : the study included 42 females of reproductive age with unipolar depression (39; 93% completed the study). Average age of patients was 33.5 ± 2.1 years. A diagnosis of depressive episode within recurrent depressive disorder was established in 17 patients (43.6%), a single depressive episode in 10 (25.6%), and dysthymia in 12 (32.4%). The patients' condition was assessed before the start of therapy in the hospital and three months later using a battery of psychometric tests (MADRS, HAM-A, Holmes-Ray Stress Rating Scale) and laboratory tests (progesterone, cortisol, total cholesterol, and C-reactive protein in blood). Results : the average total MADRS score decreased from 22.82 ± 1.2 at the beginning to 9.13 ± 1.4 ( p < 0.001) at the end point. The severity of anxiety according to the HAM-A scale decreased from 17.91 ± 0.792 to a level comparable to the population level — 6.13 ± 0.766 ( p < 0.001). 30 patients (76.9%) achieved a response. Complete remission was registered in 19 (48.7%) after treatment. Concerning the laboratory data, the cortisol level changed signi cantly -— from 409 nmol/l to 273 nmol/l ( p = 0.005), the cortisol to progesterone ratio decreased from 48.5 to 16.06 ( p = 0.006). Changes in progesterone indicators from 8.50 nmol/l to 17.51 nmol/l ( p = 0.118), total cholesterol ( p = 0.801), CRP ( p = 0.945) did not reach statistical signi cance. Cortisol levels were significantly lower in responders (242.5 ± 38.9) than in non-responders (315.2 ± 43.2), (Exp(B) = 0.413, p = 0.008). Progesterone levels were higher in responders (19.8 ± 2.3) than in non-responders (15.6 ± 3.3), (Exp(B) = 1.314, p = 0.044). Differences in total cholesterol levels between the responder and nonresponder groups (Exp(B) = 0.618, p = 0.036) are significant predictors of therapeutic response. Differences in CRP levels between responders and non-responders were not statistically signifi cant. High Holmes-Rey Depression Inventory scores (260.86 ± 12) did not associate with other psychometric and laboratory parameters. Conclusions : peripheral markers of neuroin ammation, endogenous neurosteroid system activity, and the HPA axis demonstrate signi cant changes during treatment of unipolar depression in women of reproductive age. Evaluating the ef cacy of neurosteroid analogs in antidepressive therapy is a promising direction.
- Open Access
- 3 August 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (3) , 31-43
Association between Genetic Polymorphisms of Pro- and Anti-Inflammatory Cytokines and C-Reactive Protein and Syndrome-Based Subtypes of Unipolar Depression
Background : systemic inflammation plays a central role in pathogenesis of unipolar depression. In most studies focusing on inflammatory markers, unipolar depressive disorders are regarded as a single nosological category without subtype differentiation although the extent to which inflammatory mechanisms are involved varies across syndrome-based subtypes. Genetic polymorphisms affecting the expression of pro- and anti-inflammatory cytokines IL-4, IL-10, IL-6, IL-1B and C-reactive protein (CRP) may determine the syndrome-based structure of unipolar depressive disorders. The aim of study was to investigate functionally significant single-nucleotide polymorphisms (SNPs) of IL-4, IL-10, IL-6, IL-1B and CRP genes in patients with unipolar depressive disorders and their potential associations with syndrome-based subtypes. Patients, Materials and Methods : the study enrolled patients aged 18–65 years with a verified diagnosis of unipolar depression (ICD-10 codes F32, F33, F34.1, DSM-5 codes 296.2, 296.3, 300.4) who were they undergoing treatment from May 2021 to April 2024. Genetic analysis was conducted at the Laboratory of Clinical Genetics of the FSBSI “Mental Health Research Centre”. The allocation to each syndrome-based subtype was carried out in line with the leading symptoms according to ICD-10 and DSM-5 criteria (melancholic, atypical and anxious). Genotyping was performed using the High-Resolution Melting method (HRM) run on the Applied Biosystems QuantStudio 7 Flex Real-Time PCR System (ThermoFisher, the US). Statistical analysis was conducted using the R software. Results: a total of 93 patients ( n = 93) were divided into three groups by syndrome-based subtype: melancholic (n = 34; 36.5%), atypical ( n = 19; 20.4%) and anxious ( n = 40; 43%). The A-allele of IL-10 ( rs1800872 ) was associated with the melancholic subtype (OR = 1.95, adjusted р = 0.0247). The C/C genotype of IL-4 ( rs2243250 ) and the A/A genotype of CRP ( rs2794521 ) were both associated with the atypical subtype (OR = 3.61, adjusted p = 0.0121 and OR = 3.35, adjusted p = 0.0037, respectively). The anxious subtype was associated with the T/T genotype of IL-4 ( rs2243250 ) as well as the C/C and the C/G genotypes of IL-6 ( rs1800795 ). Notably, carriers of the IL-6 ( rs1800795 ) genotypes were either at a higher or a lower risk of developing anxious depression depending on their ethnicity (OR = 6.33; adjusted p = 0.013; OR = 0.004, adjusted p = 0.006). None of the syndrome-based subtypes were associated with the IL-1B rs16944 polymorphism. Conclusions : genetic polymorphisms of IL-10, IL-4, IL-6 and CRP were shown to be significantly associated with the melancholic, atypical and anxious subtypes of unipolar depression. Further research into these polymorphisms may contribute to the development of personalized diagnostic strategies and treatments for patients with unipolar depressive disorders.
- 3 August 2026
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 24 (3) , 31-43
Open AccessAssociation between Genetic Polymorphisms of Pro- and Anti-Inflammatory Cytokines and C-Reactive Protein and Syndrome-Based Subtypes of Unipolar Depression
Background : systemic inflammation plays a central role in pathogenesis of unipolar depression. In most studies focusing on inflammatory markers, unipolar depressive disorders are regarded as a single nosological category without subtype differentiation although the extent to which inflammatory mechanisms are involved varies across syndrome-based subtypes. Genetic polymorphisms affecting the expression of pro- and anti-inflammatory cytokines IL-4, IL-10, IL-6, IL-1B and C-reactive protein (CRP) may determine the syndrome-based structure of unipolar depressive disorders. The aim of study was to investigate functionally significant single-nucleotide polymorphisms (SNPs) of IL-4, IL-10, IL-6, IL-1B and CRP genes in patients with unipolar depressive disorders and their potential associations with syndrome-based subtypes. Patients, Materials and Methods : the study enrolled patients aged 18–65 years with a verified diagnosis of unipolar depression (ICD-10 codes F32, F33, F34.1, DSM-5 codes 296.2, 296.3, 300.4) who were they undergoing treatment from May 2021 to April 2024. Genetic analysis was conducted at the Laboratory of Clinical Genetics of the FSBSI “Mental Health Research Centre”. The allocation to each syndrome-based subtype was carried out in line with the leading symptoms according to ICD-10 and DSM-5 criteria (melancholic, atypical and anxious). Genotyping was performed using the High-Resolution Melting method (HRM) run on the Applied Biosystems QuantStudio 7 Flex Real-Time PCR System (ThermoFisher, the US). Statistical analysis was conducted using the R software. Results: a total of 93 patients ( n = 93) were divided into three groups by syndrome-based subtype: melancholic (n = 34; 36.5%), atypical ( n = 19; 20.4%) and anxious ( n = 40; 43%). The A-allele of IL-10 ( rs1800872 ) was associated with the melancholic subtype (OR = 1.95, adjusted р = 0.0247). The C/C genotype of IL-4 ( rs2243250 ) and the A/A genotype of CRP ( rs2794521 ) were both associated with the atypical subtype (OR = 3.61, adjusted p = 0.0121 and OR = 3.35, adjusted p = 0.0037, respectively). The anxious subtype was associated with the T/T genotype of IL-4 ( rs2243250 ) as well as the C/C and the C/G genotypes of IL-6 ( rs1800795 ). Notably, carriers of the IL-6 ( rs1800795 ) genotypes were either at a higher or a lower risk of developing anxious depression depending on their ethnicity (OR = 6.33; adjusted p = 0.013; OR = 0.004, adjusted p = 0.006). None of the syndrome-based subtypes were associated with the IL-1B rs16944 polymorphism. Conclusions : genetic polymorphisms of IL-10, IL-4, IL-6 and CRP were shown to be significantly associated with the melancholic, atypical and anxious subtypes of unipolar depression. Further research into these polymorphisms may contribute to the development of personalized diagnostic strategies and treatments for patients with unipolar depressive disorders.
- Open Access
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 69-77
The efficacy of Laennec in combination therapy of asthenic depressions in clinical practice
Depressive spectrum disorders remain one of the most significant problems in modern clinical medicine. Despite the abundance of available treatment methods, a significant proportion of patients do not achieve complete remission, which negatively affects their prognosis.Objective: to evaluate the antidepressant, anti-asthenic and pro-cognitive effects of Laennec human placenta hydrolysate (hPH) when added to basic psychopharmacotherapy in patients with monopolar depression.Material and methods. The study was conducted at the Clinic of Psychosomatic Medicine at Sechenov University. It included patients with a verified diagnosis of monopolar depression and indications for the prescription of Laennec hPH (steatohepatitis, recurrent herpes, atopic dermatitis). The sample consisted of 60 patients. Patients were randomised into two groups of 30 people (active and control groups). Both groups received antidepressant therapy in accordance with the current recommendations of the Ministry of Health of Russia. Patients in the active group also received a course of Laennec hPH infusions, while those in the control group received a course of intravenous sham of this drug. The patients' condition was assessed before the start of therapy and 4 and 12 weeks after the start of therapy using the MADRS, MFI-20, DSST and USEFO psychometric scales.Results. Both groups showed positive dynamics on all scales studied after 4 and 12 weeks of therapy. However, significant differences in antidepressant effect between the groups were recorded only after 12 weeks of therapy (11.2±1.6 vs. 11.5±1.9 after 4 weeks and 5.6±0.9 vs. 10.6±1.0 after 12 weeks; pConclusion. The addition of Laennec hPH to basic antidepressant therapy leads to the development of a delayed but significant antidepressant, antiasthenic and pro-cognitive effect against the background of significant positive dynamics in the clinical and laboratory symptoms of diseases that are indications for the use of the drug (steatohepatitis, atopic dermatitis, recurrent herpes).
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 69-77
Open AccessThe efficacy of Laennec in combination therapy of asthenic depressions in clinical practice
Depressive spectrum disorders remain one of the most significant problems in modern clinical medicine. Despite the abundance of available treatment methods, a significant proportion of patients do not achieve complete remission, which negatively affects their prognosis.Objective: to evaluate the antidepressant, anti-asthenic and pro-cognitive effects of Laennec human placenta hydrolysate (hPH) when added to basic psychopharmacotherapy in patients with monopolar depression.Material and methods. The study was conducted at the Clinic of Psychosomatic Medicine at Sechenov University. It included patients with a verified diagnosis of monopolar depression and indications for the prescription of Laennec hPH (steatohepatitis, recurrent herpes, atopic dermatitis). The sample consisted of 60 patients. Patients were randomised into two groups of 30 people (active and control groups). Both groups received antidepressant therapy in accordance with the current recommendations of the Ministry of Health of Russia. Patients in the active group also received a course of Laennec hPH infusions, while those in the control group received a course of intravenous sham of this drug. The patients' condition was assessed before the start of therapy and 4 and 12 weeks after the start of therapy using the MADRS, MFI-20, DSST and USEFO psychometric scales.Results. Both groups showed positive dynamics on all scales studied after 4 and 12 weeks of therapy. However, significant differences in antidepressant effect between the groups were recorded only after 12 weeks of therapy (11.2±1.6 vs. 11.5±1.9 after 4 weeks and 5.6±0.9 vs. 10.6±1.0 after 12 weeks; pConclusion. The addition of Laennec hPH to basic antidepressant therapy leads to the development of a delayed but significant antidepressant, antiasthenic and pro-cognitive effect against the background of significant positive dynamics in the clinical and laboratory symptoms of diseases that are indications for the use of the drug (steatohepatitis, atopic dermatitis, recurrent herpes).
- Open Access
- 8 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 45-52
The place of neurasthenia in the structure of mental disorders in the 21st century: a series of clinical cases and a literature review
This article presents an analysis of the historical transformation of neurasthenia – from the popular “American disease” in the 19th century to exclusion from modern classifications (DSM, ICD-11). The neurologist J. Bird associated neurasthenia with “exhaustion” due to the transition from a traditional rural lifestyle to a fast-paced urban life. He was the first to describe a wide range of both mental and somatized symptoms. Later, the concept was reinterpreted in European psychiatry through the prism of intrapersonal conflicts, and in the Russian school of I.P. Pavlov’s neurasthenia was considered as an asthenic neurosis, represented by two main clinical forms: hyposthenic (with a predominance of weakness and lethargy) and hyperesthetic (with irritability and increased excitability). In ICD-10, neurasthenia remains as a diagnosis characterized by persistent fatigue from both physical and emotional stress, vegetative disorders and emotional lability, but in recent decades its diagnostic boundaries have significantly narrowed. This is due to the development of diagnostics and conceptualization of depression, anxiety and somatoform disorders, as well as the emergence of the concept of chronic fatigue syndrome, which is especially relevant in the post-covid period. In the framework of the presented study, the authors analyze the modern scientific discourse that examines the question of the clinical validity and diagnostic value of maintaining neurasthenia as an independent nosological unit in modern classifications of mental disorders. This publication also presents three clinical cases, using the example of which it will be possible to trace the main aspects of the clinical picture, differential diagnosis and approaches to the treatment of neurasthenia and related disorders.
- 8 August 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 45-52
Open AccessThe place of neurasthenia in the structure of mental disorders in the 21st century: a series of clinical cases and a literature review
This article presents an analysis of the historical transformation of neurasthenia – from the popular “American disease” in the 19th century to exclusion from modern classifications (DSM, ICD-11). The neurologist J. Bird associated neurasthenia with “exhaustion” due to the transition from a traditional rural lifestyle to a fast-paced urban life. He was the first to describe a wide range of both mental and somatized symptoms. Later, the concept was reinterpreted in European psychiatry through the prism of intrapersonal conflicts, and in the Russian school of I.P. Pavlov’s neurasthenia was considered as an asthenic neurosis, represented by two main clinical forms: hyposthenic (with a predominance of weakness and lethargy) and hyperesthetic (with irritability and increased excitability). In ICD-10, neurasthenia remains as a diagnosis characterized by persistent fatigue from both physical and emotional stress, vegetative disorders and emotional lability, but in recent decades its diagnostic boundaries have significantly narrowed. This is due to the development of diagnostics and conceptualization of depression, anxiety and somatoform disorders, as well as the emergence of the concept of chronic fatigue syndrome, which is especially relevant in the post-covid period. In the framework of the presented study, the authors analyze the modern scientific discourse that examines the question of the clinical validity and diagnostic value of maintaining neurasthenia as an independent nosological unit in modern classifications of mental disorders. This publication also presents three clinical cases, using the example of which it will be possible to trace the main aspects of the clinical picture, differential diagnosis and approaches to the treatment of neurasthenia and related disorders.
- Open Access
- 16 December 2024
- Published by Consilium Medicum in Consilium Medicum
- Vol. 26 (11) , 776-781
Prevalence and structure of sleep disorders in neurological, psychiatric and somatic hospitals
Background. Today it is well known that the structure of sleep disorders and frequency of complaints about sleep disorders depend on the diseases profile. Emotional and behavioral features of patients with different disease profile are important factors affecting the development of sleep disorders. Aim. To estimate difference of sleep disorders according to the profile of the disease and to assess the emotional and psychological factors that may influence sleep disorders. Materials and methods. A total of 300 patients participated in the study: 100 from every department (neurological, psychiatric and pulmonological). To assess the quality of sleep Pittsburgh Sleep Quality Index was used; data from the Spielberger anxiety scale, a 5-factor personality questionnaire, and a questionnaire for evaluating coping strategies (coping strategies) were used to assess personal and emotional factors. Results. Patients from the psychotherapeutic group appeared to be more likely to complain of sleep disorders in general. They also had an average Pittsburgh Sleep Quality Index score higher than patients from neurological and somatic hospitals. In the group of patients with a neurological profile loud snoring is more often reason for sleep disturbing. Awakenings due to difficulties in breathing were more often detected in the group of somatic profile. Situational and personal anxiety influenced the structure of sleep disorders regardless of the disease profile. Conclusion. The use of various coping strategies has the greatest impact on the presence of sleep disorders in the group of patients with a somatic profile, to a lesser extent – in the group of neurological profile.
- 16 December 2024
- Published by Consilium Medicum in Consilium Medicum
- Vol. 26 (11) , 776-781
Open AccessPrevalence and structure of sleep disorders in neurological, psychiatric and somatic hospitals
Background. Today it is well known that the structure of sleep disorders and frequency of complaints about sleep disorders depend on the diseases profile. Emotional and behavioral features of patients with different disease profile are important factors affecting the development of sleep disorders. Aim. To estimate difference of sleep disorders according to the profile of the disease and to assess the emotional and psychological factors that may influence sleep disorders. Materials and methods. A total of 300 patients participated in the study: 100 from every department (neurological, psychiatric and pulmonological). To assess the quality of sleep Pittsburgh Sleep Quality Index was used; data from the Spielberger anxiety scale, a 5-factor personality questionnaire, and a questionnaire for evaluating coping strategies (coping strategies) were used to assess personal and emotional factors. Results. Patients from the psychotherapeutic group appeared to be more likely to complain of sleep disorders in general. They also had an average Pittsburgh Sleep Quality Index score higher than patients from neurological and somatic hospitals. In the group of patients with a neurological profile loud snoring is more often reason for sleep disturbing. Awakenings due to difficulties in breathing were more often detected in the group of somatic profile. Situational and personal anxiety influenced the structure of sleep disorders regardless of the disease profile. Conclusion. The use of various coping strategies has the greatest impact on the presence of sleep disorders in the group of patients with a somatic profile, to a lesser extent – in the group of neurological profile.
- Open Access
- 14 August 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 52-60
Anxiety Disorders in Clinical Practice (Clinical Observation and Literature Review)
Anxiety disorders are the most common group of mental disorders. The high prevalence of anxiety disorders and their negative impact on the functioning and quality of life of patients determines the need for timely diagnosis and therapy. The review presents data on the clinical manifestations of anxiety, as well as on the main forms of anxiety disorders according to current classifications of mental disorders. An analysis is conducted on the relationship between somatic and cognitive manifestations of anxiety, explaining the difficulties in diagnosing and treating patients with a predominance of somatic symptoms. Cognitive features specific to patients with anxiety disorders are described. Approaches to the diagnosis and differential diagnosis of anxiety disorders are provided, along with information on main psychometric scales. The importance of a clinical approach in diagnosing anxiety disorders is justified, and the role of para-clinical methods in establishing a diagnosis is described. According to recent consensus documents and clinical guidelines, the first-line therapies for anxiety disorders are cognitive-behavioral therapy and the use of selective serotonin reuptake inhibitors; the basics of both methods are described. Considering current research, both approaches have drawbacks, which necessitates the use of medication with an alternative mechanism of action. One such medication is the modern multimodal anxiolytic Aviandr, which has demonstrated high effectiveness and safety in treating patients with the most severe form of anxiety disorders – generalized anxiety disorder. The main points of the review are illustrated with a clinical example of the successful use of Aviandr in a patient with generalized anxiety disorder.
- 14 August 2024
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 12,p. 52-60
Open AccessAnxiety Disorders in Clinical Practice (Clinical Observation and Literature Review)
Anxiety disorders are the most common group of mental disorders. The high prevalence of anxiety disorders and their negative impact on the functioning and quality of life of patients determines the need for timely diagnosis and therapy. The review presents data on the clinical manifestations of anxiety, as well as on the main forms of anxiety disorders according to current classifications of mental disorders. An analysis is conducted on the relationship between somatic and cognitive manifestations of anxiety, explaining the difficulties in diagnosing and treating patients with a predominance of somatic symptoms. Cognitive features specific to patients with anxiety disorders are described. Approaches to the diagnosis and differential diagnosis of anxiety disorders are provided, along with information on main psychometric scales. The importance of a clinical approach in diagnosing anxiety disorders is justified, and the role of para-clinical methods in establishing a diagnosis is described. According to recent consensus documents and clinical guidelines, the first-line therapies for anxiety disorders are cognitive-behavioral therapy and the use of selective serotonin reuptake inhibitors; the basics of both methods are described. Considering current research, both approaches have drawbacks, which necessitates the use of medication with an alternative mechanism of action. One such medication is the modern multimodal anxiolytic Aviandr, which has demonstrated high effectiveness and safety in treating patients with the most severe form of anxiety disorders – generalized anxiety disorder. The main points of the review are illustrated with a clinical example of the successful use of Aviandr in a patient with generalized anxiety disorder.
- Open Access
- 20 August 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 288-296
The use of biofeedback techniques in clinical practice
In the past decades, biofeedback has become a widely adopted non-pharmacological option in the management of a variety of somatic, neurological, and psychiatric conditions. The biofeedback method is based on the associations between one’s vegetative and mental functions; during a session with the device, information about the change in his/her condition over time is “returned” to the patient as accessible audial or visual stimuli. The efficacy of biofeedback treatment may primarily be attributed to improvements in the state of the patients based on establishing an individual model of his/her best psychophysiological state, enabling effective rehabilitation activities at a rate suitable for each patient along with ensuring better awareness of the patient of his/her body functions; such an intervention is stepwise and helps sustain the patient’s motivation for success, thus affecting the pathological condition. This review describes the historical prerequisites for the development of biofeedback techniques and the principal mechanisms of their action; a brief summary of studies looking at the efficacy of this method in various somatic, neurological, and psychiatric conditions is also provided. The presented data clearly indicate that the use of biofeedback results in a decreased medication load in patients suffering from conditions such as arterial hypertension, epilepsy, ADHD, chronic pain, anxiety disorders, autism etc. while there are practically no contraindications for this method, except for acute psychosis, photosensitive epilepsy, and severe cognitive impairment. In this connection, clinical implementation of biofeedback techniques should be intensified in a variety of conditions.
- 20 August 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 288-296
Open AccessThe use of biofeedback techniques in clinical practice
In the past decades, biofeedback has become a widely adopted non-pharmacological option in the management of a variety of somatic, neurological, and psychiatric conditions. The biofeedback method is based on the associations between one’s vegetative and mental functions; during a session with the device, information about the change in his/her condition over time is “returned” to the patient as accessible audial or visual stimuli. The efficacy of biofeedback treatment may primarily be attributed to improvements in the state of the patients based on establishing an individual model of his/her best psychophysiological state, enabling effective rehabilitation activities at a rate suitable for each patient along with ensuring better awareness of the patient of his/her body functions; such an intervention is stepwise and helps sustain the patient’s motivation for success, thus affecting the pathological condition. This review describes the historical prerequisites for the development of biofeedback techniques and the principal mechanisms of their action; a brief summary of studies looking at the efficacy of this method in various somatic, neurological, and psychiatric conditions is also provided. The presented data clearly indicate that the use of biofeedback results in a decreased medication load in patients suffering from conditions such as arterial hypertension, epilepsy, ADHD, chronic pain, anxiety disorders, autism etc. while there are practically no contraindications for this method, except for acute psychosis, photosensitive epilepsy, and severe cognitive impairment. In this connection, clinical implementation of biofeedback techniques should be intensified in a variety of conditions.
- Open Access
- 30 April 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (2) , 98-105
Diagnosis and therapy of obsessive-compulsive spectrum disorders in general medical and neurological practice
Obsessive-compulsive spectrum disorders are widely represented in the population and often encountered in clinical practice, but they are not well diagnosed and many patients do not receive proper treatment. This review discusses the prevalence of obsessive-compulsive spectrum disorders, their negative impact on the level of functioning of patients, comorbidity with other mental disorders, diagnosis and differential diagnosis. The emphasis is put on changes in approaches to the diagnosis of obsessive-compulsive disorders that will occur after the introduction of the International Classification of Diseases of the 11th revision (ICD-11). Approaches to the treatment of obsessive-compulsive spectrum disorders are discussed in accordance with the principles of evidence-based medicine, and the use of selective serotonin reuptake inhibitors and cognitive behavioral therapy as first-line therapy is justified.
- 30 April 2023
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 15 (2) , 98-105
Open AccessDiagnosis and therapy of obsessive-compulsive spectrum disorders in general medical and neurological practice
Obsessive-compulsive spectrum disorders are widely represented in the population and often encountered in clinical practice, but they are not well diagnosed and many patients do not receive proper treatment. This review discusses the prevalence of obsessive-compulsive spectrum disorders, their negative impact on the level of functioning of patients, comorbidity with other mental disorders, diagnosis and differential diagnosis. The emphasis is put on changes in approaches to the diagnosis of obsessive-compulsive disorders that will occur after the introduction of the International Classification of Diseases of the 11th revision (ICD-11). Approaches to the treatment of obsessive-compulsive spectrum disorders are discussed in accordance with the principles of evidence-based medicine, and the use of selective serotonin reuptake inhibitors and cognitive behavioral therapy as first-line therapy is justified.
- 21 April 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (4) , 31-36
A role of neurosteroids in the pathogenesis of psychiatric disorders
Несмотря на доказанную значимость нейростероидов (НС) во многих физиологических процессах, их роль в патогенезе большинства психических заболеваний остается сравнительно малоизученной. В обзоре приводятся клинические данные о влиянии НС на формирование и терапию тревожного расстройства, депрессии, биполярного расстройства и шизофрении. В частности, указывается на неоднозначный характер воздействия НС на ГАМКА- и другие рецепторы. Особый интерес представляет анксиолитический и анксиогенный эффект некоторых НС, антидепрессивный эффект аллопрегнанолона в лечении послеродовой и других форм депрессий, природа кратко-и долгосрочных механизмов антидепрессивных эффектов НС разного вида. Также обсуждается на данный момент пока недоказанная гипотеза о влиянии изменения уровня НС на течение биполярного расстройства, проводится анализ научных данных о развитии шизофренической симптоматики в связи с изменением уровня НС в контексте позитивных и когнитивных симптомов.
- 21 April 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (4) , 31-36
A role of neurosteroids in the pathogenesis of psychiatric disorders
Несмотря на доказанную значимость нейростероидов (НС) во многих физиологических процессах, их роль в патогенезе большинства психических заболеваний остается сравнительно малоизученной. В обзоре приводятся клинические данные о влиянии НС на формирование и терапию тревожного расстройства, депрессии, биполярного расстройства и шизофрении. В частности, указывается на неоднозначный характер воздействия НС на ГАМКА- и другие рецепторы. Особый интерес представляет анксиолитический и анксиогенный эффект некоторых НС, антидепрессивный эффект аллопрегнанолона в лечении послеродовой и других форм депрессий, природа кратко-и долгосрочных механизмов антидепрессивных эффектов НС разного вида. Также обсуждается на данный момент пока недоказанная гипотеза о влиянии изменения уровня НС на течение биполярного расстройства, проводится анализ научных данных о развитии шизофренической симптоматики в связи с изменением уровня НС в контексте позитивных и когнитивных симптомов.
- Open Access
- 11 April 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 110-118
Anxiety disorders in general medical practice – clinical picture, diagnosis, optimized approaches to therapy
Anxiety disorders are widespread in the population and in general medical practice and have a pronounced negative impact on the quality of life and functioning of patients. Currently, the prerequisites for the diagnosis and treatment of anxiety disorders outside the psychiatric network are accumulating by therapists, general practitioners and other non-psychiatric doctors. A review of the most significant factors contributing to a wider diagnosis and treatment of anxiety disorders in general medical practice is given. This review presents modern ideas about the pathogenesis of anxiety disorders, substantiates the modern idea of their multifactorial nature, the contribution of genetic and epigenetic, psychological and social factors, outlines the concepts of the neurobiological basis of pathological anxiety based on neuroimaging studies. In the future, information is provided on the general manifestations of anxiety disorders, the main clusters of anxiety, the systematics of anxiety disorders according to ICD-10. Modern ideas about the diagnosis of anxiety disorders using both scales and a clinical approach are given, a detailed review of currently available diagnostic scales validated for clinical practice is presented. The main approaches to conducting a clinical conversation are also presented, recommendations are given for the most successful collection of information about the clinical condition of patients. At the end of the review, information is given on existing approaches to psychopharmacotherapy and psychotherapy of anxiety disorders. Taking into account pharmacological and clinical studies, the place of drugs tofisopam (an atypical allosteric modulator of GABA receptors) and buspirone (a partial agonist of serotonin 1A receptors) in the treatment of anxiety disorders in general medical practice has been argued.
- 11 April 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 3,p. 110-118
Open AccessAnxiety disorders in general medical practice – clinical picture, diagnosis, optimized approaches to therapy
Anxiety disorders are widespread in the population and in general medical practice and have a pronounced negative impact on the quality of life and functioning of patients. Currently, the prerequisites for the diagnosis and treatment of anxiety disorders outside the psychiatric network are accumulating by therapists, general practitioners and other non-psychiatric doctors. A review of the most significant factors contributing to a wider diagnosis and treatment of anxiety disorders in general medical practice is given. This review presents modern ideas about the pathogenesis of anxiety disorders, substantiates the modern idea of their multifactorial nature, the contribution of genetic and epigenetic, psychological and social factors, outlines the concepts of the neurobiological basis of pathological anxiety based on neuroimaging studies. In the future, information is provided on the general manifestations of anxiety disorders, the main clusters of anxiety, the systematics of anxiety disorders according to ICD-10. Modern ideas about the diagnosis of anxiety disorders using both scales and a clinical approach are given, a detailed review of currently available diagnostic scales validated for clinical practice is presented. The main approaches to conducting a clinical conversation are also presented, recommendations are given for the most successful collection of information about the clinical condition of patients. At the end of the review, information is given on existing approaches to psychopharmacotherapy and psychotherapy of anxiety disorders. Taking into account pharmacological and clinical studies, the place of drugs tofisopam (an atypical allosteric modulator of GABA receptors) and buspirone (a partial agonist of serotonin 1A receptors) in the treatment of anxiety disorders in general medical practice has been argued.